Home » Topics » Ocular, BioWorld Science

Ocular, BioWorld Science
RSS

PhotoVision in-licenses novel technology for development of AMD treatment

April 7, 1999

Xalatan approved in Japan for glaucoma and ocular hypertension

March 16, 1999

Licensing opportunity from the NIH: antiinflammatory cytokine

March 4, 1999

Placebo-controlled study supports the efficacy of Alrex in seasonal allergic conjunctivitis

March 1, 1999

Worldwide strategic alliance established by Agennix and Santen for lactoferrin

Feb. 26, 1999

Novel antioxidant/antiproliferative NSAID esters and amides designed by Alcon

Feb. 19, 1999

CoCensys enters research agreements with Senju and Parke-Davis

Feb. 18, 1999

FDA says KeraVision's treatment for myopia approvable

Feb. 17, 1999

Patient enrollment completed in loteprednol/antibiotic combination study

Feb. 11, 1999

Sunrise LTK System PMA accepted for filing by FDA

Feb. 11, 1999

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...